



**REMARKS**

Claim 10 has been amended to correct a typographical error and to add the term “optional.” Support for the amendments may be found through out the as-filed specification, for example, on pages 46 and 47. Applicants submit that the new claims 30-53 are supported by the application as-filed and attest no new matter has been added as a result of the amendment. Applicants herein acknowledge the restriction requirement in the above-referenced application. In response to the election of an invention to be examined, Applicants hereby elect, without traverse, invention II, Claims 10-14 and new Claims 30-53, drawn to a method of inhibiting a kinase comprising administering a compound of formula,



classified in class 548, subclass 400.

In response to the election of a single disclosed species, Applicants hereby elect without traverse:



Applicants submit that claims 10, 12, 14, 30-33, 43, 46, 47, 49, and 51-53 read upon the elected species. Applicants respectfully request consideration of the non-elected species upon acknowledgement of the allowability of claim 10.

**CONCLUSION**

A petition for a one-month extension of time is attached herewith. It is not believed that any other time extension or fees are required with this response. If this is incorrect, an extension of time as deemed necessary is hereby requested, and the Commissioner is hereby authorized to charge any deficiency or credit any over payment to Deposit Account no. **50-1627**. An early Office Action on the merits is respectfully solicited.

Respectfully submitted,

/Andrew Gibbs/

Andrew Gibbs  
Registration No. 52,943

Intellectual Property Department  
**Myriad Genetics, Inc.**  
**(Customer No. 26698)**  
320 Wakara Way  
Salt Lake City, UT 84108  
Telephone: 801-584-3600  
Fax: 801-584-3640

Date: March 7, 2008